Clinical trialNCT06184750RecruitingPhase 2Interventional

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

SponsorNational Cancer Institute (NCI)Enrollment200Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In SituEstrogen Receptor-Positive Breast Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Seema A Khan
Northwestern University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Arizona Cancer Center - Prevention Research Clinic
Tucson, Arizona, United States
Sima Ehsani Chimeh
Recruiting
Northwestern University
Chicago, Illinois, United States
Seema A. Khan
Recruiting
University of Illinois College of Medicine - Chicago
Chicago, Illinois, United States
Kent F. Hoskins
Recruiting
University of Kansas Cancer Center
Kansas City, Kansas, United States
Carol J. Fabian →
Recruiting
Brigham and Women'S Hospital
Boston, Massachusetts, United States
Withdrawn
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Judy E. Garber
Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Melissa L. Pilewskie
Recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Adetunji T. Toriola
Recruiting
Case Western Reserve University
Cleveland, Ohio, United States
Amanda L. Amin
Recruiting
Medical University of South Carolina
Charleston, South Carolina, United States
Kevin S. Hughes
Recruiting
Ut Md Anderson Cancer Center
Houston, Texas, United States
Parijatham (Priya) S. Thomas
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tamoxifen →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Sept 2024
Primary completion: 31 Mar 2028
Completion: 30 Sept 2028
Last update posted: 27 Jul 2026
Registered enrollment: 200
Registry id: NCT06184750

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.